Adverse event rates, events/100 PY | ||||
---|---|---|---|---|
Tocilizumab | Abatacept | Ratio (95% CI) of rates tocilizumab/abatacept | p value | |
Cancera | 0.61 events/155.2 PY | 1.22 events/157.2 PY | 0.5 (0.1, 9.7) | 0.63 |
Infection | ||||
All events | 54.373 events/135.4 PY | 57.179 events/138.3 PY | 0.9 (0.7, 1.3) | 0.72 |
Serious infections | 1.93 events/155.2 PY | 2.54 events/157.7 PY | 0.7 (0.1, 4.5) | 0.74 |
Cardiovascular | 2.54 events/154.6 PY | 1.93 events/156.7 PY | 1.3 (0.2, 9.2) | 0.71 |